Positive Phase 3 Results and Strong Financial Position Support Buy Rating for Vor Biopharma

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Vor Biopharma and keeping the price target at $3.00.

Swayampakula Ramakanth has given his Buy rating due to a combination of factors influencing Vor Biopharma’s prospects. The recent positive results from a Phase 3 clinical study in China, conducted by Vor’s partner RemeGen, demonstrated that telitacicept significantly improved Sjögren’s disease activity compared to a placebo, while maintaining a favorable safety profile. This outcome not only reduces the risk associated with telitacicept but also opens the possibility for label expansion in the U.S., potentially enhancing Vor’s market opportunities.
Furthermore, Vor Biopharma’s financial position appears stable, with approximately $200.6 million in cash and equivalents, which is expected to support operations into the first quarter of 2027. Despite reporting no revenues and a net loss in the second quarter of 2025, the company’s strategic plans to initiate a pivotal study in the U.S. for Sjögren’s syndrome could provide significant upside to its current financial model. The valuation, based on a risk-adjusted net present value analysis, supports a 12-month price target of $3.00 per share, reinforcing the Buy recommendation.

According to TipRanks, Ramakanth is a 4-star analyst with an average return of 7.3% and a 38.00% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Precigen, and Eton Pharmaceuticals.